1. Alisporivir for use in the treatment of chronic hepatitis C virus infection of genotype 1 in a patient with IL28B non-C / C.2 genotype. Alisporivir for use in the treatment of chronic hepatitis C virus infection of genotype 1 in a patient with IL28B C / C.3. Alisporivir for use according to claim 1 or 2, wherein alisporivir is administered during the initial phase in an amount of about 600 mg twice a day, followed by the administration of alisporivir during the second phase in an amount of from about 600 to about 800 mg once a day. Alisporivir for use according to claim 1 or 2, characterized in that alisporivir is administered during the initial phase in an amount of about 600 mg twice a day for 7 days, followed by the administration of alisporivir during the second phase in an amount of from about 600 mg to about 800 mg once a day for a period of up to 23, 47 or 71 weeks. 5. Alisporivir for use according to claim 4, characterized in that alisporivir is administered during the initial phase in an amount of approximately 600 mg twice daily for 7 days, followed by the administration of alisporivir during the second phase in an amount of 600 mg once a day for a period of up to 47 weeks. 6. Alisporivir for use according to claim 1, wherein alisporivir is administered in combination with interferon, with ribavirin. 7. A method for treating chronic hepatitis C virus infection of genotype 1 in a patient with IL28B non-C / C genotype, comprising administering alisporivir to the patient during the initial phase in an amount of approximately 600 mg twice daily for 7 days, followed by the administration of alisporivir during the second phase in an amount from about 600 to about 800 mg once1. Алиспоривир для применения при лечении хронической инфекции вируса гепатита С генотипа 1 у пациента с генотипом IL28B не-С/C.2. Алиспоривир для применения при лечении хронической инфекции вируса гепатита С генотипа 1 у пациента с генотипом IL28B С/C.3. Алиспоривир для применения по п. 1
